Concord Drugs' Q4 FY 2025-26 Quarterly Results

Result Summary

• Concord Drugs Ltd reported a 123.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 264.4%.
• Its expenses for the quarter were up by 122.6% QoQ and 259.3% YoY.
• The net profit increased 140.9% QoQ and increased 1225.0% YoY.
• The earnings per share (EPS) of Concord Drugs Ltd stood at 0.47 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Concord Drugs Ltd is a pharmaceutical company specializing in the development, manufacturing, and marketing of generic and branded pharmaceuticals. The company primarily operates within the healthcare sector, focusing on providing affordable medication solutions. As of the latest updates available up to October 2023, Concord Drugs Ltd has been engaged in expanding its product line to include advanced pharmaceutical formulations and has been active in exploring international markets to enhance its global presence. Specific recent developments or strategic initiatives for the timeframe including Q4FY26 are not explicitly detailed in the available data.

Revenue

During Q4FY26, Concord Drugs Ltd reported a total income of ₹37.90 crores, reflecting a significant increase of 123.1% from ₹16.99 crores in the previous quarter (Q3FY26) and a remarkable year-over-year growth of 264.4% compared to ₹10.40 crores in Q4FY25. This substantial rise in revenue indicates a robust performance for the quarter. The growth in total income can be attributed to possible factors such as an increase in sales volume, higher demand for its pharmaceutical products, or the successful introduction of new product lines. Detailed revenue breakdowns by product or geographical segments are not provided, but the overall figures suggest a strong quarter in terms of revenue generation.

Profitability

Concord Drugs Ltd's profitability metrics for Q4FY26 show significant improvement. The profit before tax (PBT) stood at ₹0.75 crores, representing an increase of 150.0% from ₹0.30 crores in Q3FY26 and a substantial year-over-year growth of 1150.0% from ₹0.06 crores in Q4FY25. The tax expense for Q4FY26 was ₹0.22 crores, which is a rise of 175.0% from ₹0.08 crores in the previous quarter and 1000.0% from ₹0.02 crores in Q4FY25. Consequently, the profit after tax (PAT) for Q4FY26 was ₹0.53 crores, marking a 140.9% increase quarter-over-quarter and a 1225.0% increase year-over-year. Earnings per share (EPS) for the quarter was ₹0.47, up from ₹0.16 in Q3FY26 and ₹0.04 in Q4FY25, showing a QoQ growth of 193.7% and a YoY growth of 1075.0%.

Operating Metrics

The overall operating metrics for Concord Drugs Ltd during Q4FY26 reveal significant changes. The total expenses for the quarter were ₹37.15 crores, which increased by 122.6% from ₹16.69 crores in Q3FY26 and 259.3% from ₹10.34 crores in Q4FY25. This increase in expenses may be associated with higher production costs, increased research and development expenditures, or expansion-related expenses. Despite the rise in expenses, the company maintained a positive profit before tax and profit after tax for the quarter, indicating effective management of operating costs relative to revenue growth. Detailed information on specific cost components or operational efficiency measures is not available in the provided data.